Pieris Pharmaceuticals Inc (NASDAQ:PIRS)’s share price shot up 15.2% during mid-day trading on Wednesday . The company traded as high as $7.37 and last traded at $7.34. 1,445,500 shares were traded during mid-day trading, an increase of 135% from the average session volume of 616,394 shares. The stock had previously closed at $6.37.

A number of brokerages have issued reports on PIRS. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 20th. ValuEngine cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $9.00.

The firm has a market capitalization of $328.79, a P/E ratio of -9.97 and a beta of -76.07.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The firm had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $1.52 million. The firm’s revenue was up 400.3% on a year-over-year basis. analysts predict that Pieris Pharmaceuticals Inc will post -0.72 earnings per share for the current fiscal year.

In other news, major shareholder Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock in a transaction on Monday, December 18th. The shares were sold at an average price of $5.70, for a total transaction of $841,519.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.05% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $2,377,000. Northern Trust Corp acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $1,625,000. Renaissance Technologies LLC acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter worth $661,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $649,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $526,000. 50.45% of the stock is currently owned by institutional investors.

WARNING: “Pieris Pharmaceuticals (PIRS) Shares Up 15.2%” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/27/pieris-pharmaceuticals-pirs-shares-up-15-2.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.